Reference : Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by in...
Scientific journals : Article
Human health sciences : Hematology
Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation.
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Lippincott Williams & Wilkins
Yes (verified by ORBi)
[en] Adult ; Cyclosporine/administration & dosage/blood ; Erythropoiesis/drug effects/physiology ; Erythropoietin/biosynthesis/blood/deficiency ; Erythropoietin, Recombinant/administration & dosage ; Female ; Graft Rejection/drug therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunosuppressive Agents/administration & dosage/blood ; Leukemia/therapy ; Lymphoma/therapy ; Male ; Middle Aged ; Mycophenolic Acid/administration & dosage/analogs & derivatives ; Receptors, Transferrin/blood ; Transplantation Conditioning ; Transplantation, Homologous
[en] BACKGROUND: It is now well established that after conventional allogeneic hematopoietic stem-cell transplantation (HSCT), erythropoietic recovery is impaired because erythropoietin (Epo) production remains inadequate for prolonged periods of time. However, erythropoietic reconstitution after nonmyeloablative SCT (NMSCT) has never been characterized. METHODS: Twelve patients received a nonmyeloablative conditioning regimen consisting of 2 Gy total body irradiation (TBI) alone (n=6), 2 Gy TBI and fludarabine (n=3), or cyclophosphamide and fludarabine (n=3), followed by transplantation of allogeneic peripheral blood stem cells. Graft-versus-host-disease (GvHD) prophylaxis was carried out with mycophenolate mofetil (from day -1 to day 28) plus cyclosporine (from day -1 to day 120 or longer in case of chronic GvHD). Erythropoiesis was quantitated by soluble transferrin receptor (sTfR) levels, and the adequacy of Epo production was evaluated by the observed-to-predicted Epo ratio (O/P Epo). RESULTS: Mean sTfR levels decreased following the conditioning regimen but remained well within the normal range throughout the posttransplant period. The O/P Epo ratio presented an initial surge quite similar to that observed after conventional conditioning. Thereafter, the O/P Epo ratio normalized rapidly, and Epo levels remained adequate during the whole observation period. CONCLUSION: Contrarily to what is observed after myeloablative transplant, Epo levels remained adequate after NMSCT, resulting in normal erythropoiesis. These results suggest that the administration of erythropoietin therapy (rHuEpo) could be less effective after NMSCT than after conventional allogeneic transplant.

File(s) associated to this reference

Fulltext file(s):

Open access
Epo-serum minitransplant.Transplantation.pdfPublisher postprint227.28 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.